Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience

References

• Fiore AE, Shay DK, Haber P et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) 2007. MMWR Morb. Mortal. Wkly Rep.56(RR-6), 1–60 (2007).
   PubMedGoogle Scholar
• US Department of Health and Human Services. Pandemic Influenza Preparedness and Response Plan. Annex 11: lessons learned from 1976 Swine Influenza Program. (2004).
   Google Scholar
• Fauci AS. Race against time. Nature435(7041), 423–424 (2005).
   Google Scholar
• Wood JM, Robertson JS. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol.2(10), 842–847 (2004).
   PubMed Web of Science ®Google Scholar
• Sheets R, Petricciani J. Vaccine cell substrates 2004. Expert Rev. Vaccines3(6), 633–638 (2004).
   Google Scholar
• Ellenberg SS, Chen RT. The complicated task of monitoring vaccine safety. Public Health Rep.112(1), 10–20; discussion 21 (1997).
   PubMed Web of Science ®Google Scholar
• Enserink M. Avian influenza. ‘Pandemic vaccine’ appears to protect only at high doses. Science309(5737), 996 (2005).
   PubMedGoogle Scholar
• Fritzell B. Detection of adverse events: what are the current sensitivity limits during clinical development. Vaccine20, S47–S48 (2002).
   Google Scholar
• Bohlke K, Davis RL, Marcy SM et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics112(4), 815–20 (2003).
   PubMed Web of Science ®Google Scholar
• Haber P, DeStefano F, Angulo F et al. Guillain–Barré syndrome following influenza vaccination. JAMA292(20), 2478–2481 (2004).
   PubMed Web of Science ®Google Scholar
• Lasky T, Terracciano GJ, Magder L et al. The Guillain–Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N. Engl. J. Med.339, 1797–1802 (1998).
   PubMed Web of Science ®Google Scholar
• Arness MK, Eckart RE, Love SS et al. Myopericarditis following smallpox vaccination. Am. J. Epidemiol.160(7), 642–651 (2004).
   PubMed Web of Science ®Google Scholar
• Halsey N. The science of evaluation of adverse events associated with vaccination. Semin. Pediatr. Infect. Dis.13, 205–214 (2002).
   Google Scholar
• Bureau of Infectious Diseases. Oculo-respiratory syndrome in association with the influenza vaccine: Canada, October–November 2000. Can. Commun. Dis. Rep.26(23), 1–2 (2000).
   Google Scholar
• Khromova A, Pool V, Chen R. Oculo-respiratory syndrome (ORS) following influenza vaccine – United States, 1990–2002: new or previously unrecognized? Presented at: 2003 Epidemic Intelligence Service Conference. Atlanta, GA, USA, 22–26 April 2003.
   Google Scholar
• Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am. J. Epidemiol.110(2), 105–123 (1979).
   PubMed Web of Science ®Google Scholar
• Iskander J, Haber P, Herrera G. Monitoring vaccine safety during an influenza pandemic. Yale J. Biol. Med.78(5), 265–275 (2005).
   Google Scholar
• Izurieta HS, Haber P, Wise et al. Adverse events reported following live cold-adapted, intranasal influenza vaccine. JAMA294(21), 2720–2725 (2005).
   PubMed Web of Science ®Google Scholar
• Belshe R, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med.685–696 (2007).
   Google Scholar
• Bergen R, Black S, Lewin E et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediar. Infect. Dis. J.23, 138–144 (2004).
   PubMed Web of Science ®Google Scholar
• Varricchio F, Iskander J, Destefano F et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr. Infect. Dis. J.23, 287–294 (2004).
   PubMed Web of Science ®Google Scholar
• CDC. Intussusception among recipients of rotavirus vaccine – United States, 1998–1999. MMWR Morb. Mortal. Wkly Rep.48, 577–581 (1999).
   PubMedGoogle Scholar
• Rosenthal S, Chen RT. Reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am. J. Public Health85, 1706–1709 (1995).
   PubMedGoogle Scholar
• Verstraeten T, Baughman AL, Cadwell B et al. Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination. Am. J. Epidemiol.154(11), 1006–1012 (2001).
   Google Scholar
• Kohl KS, Gidudu J, Bonhoeffer J et al. The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine25(31), 5671–5674 (2007).
   PubMed Web of Science ®Google Scholar
• Zhou W, Pool V, Iskander J et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) – United States, 1991–2001. In: CDC surveillance summaries (January 24). MMWR Morb. Mortal. Wkly Rep.52(No. SS-1) (2003).
   Google Scholar
• Chen RT, Glasser JW, Rhodes PH et al. The Vaccine Safety Datalink Project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics99, 765–773 (1997).
   PubMed Web of Science ®Google Scholar
• Kramarz P, France EK, Destefano F et al. Population-based study of rotavirus vaccination and intussusception. Pediatr. Infect. Dis. J.20(4), 410–416 (2001).
   PubMed Web of Science ®Google Scholar
• France EK, Glanz JM, Xu S et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch. Pediatr. Adolesc. Med.158(11), 1031–1036 (2004).
   PubMed Web of Science ®Google Scholar
• Davis RL, Kolczak M, Lewis E et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology16(3), 336–341 (2005).
   PubMed Web of Science ®Google Scholar
• Breiman RF, Zanca JA. Of floors and ceilings – defining, assuring, and communicating vaccine safety. Am. J. Public Health87(12), 1919–1920 (1997).
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Katona P, Hurwitz ES et al. Guillain–Barré syndrome in the United States, 1979–1980 and 1980–1981. Lack of an association with influenza vaccination. JAMA248(6), 698–700 (1982).
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Immunization Safety Review: Influenza Vaccines and Neurological Complications. National Academies Press, Washington, DC, USA (2003).
   Google Scholar
• Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med.350(9), 896–903 (2004).
   PubMed Web of Science ®Google Scholar
• Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell’s palsy. N. Engl. J. Med.350(9), 860–861 (2004).
   PubMed Web of Science ®Google Scholar
• Zhou W, Pool V, DeStefano F et al. A potential signal of Bell’s palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS) – United States, 1991–2001. Pharmacoepidemiol. Drug Saf.13(8), 505–510 (2004).
   PubMedGoogle Scholar
• McMahon A, Iskander J, Haber P et al. Adverse events alter inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990–2003. Pediatrics115(2), 453–460 (2005).
   PubMedGoogle Scholar
• Hambridge SJ, Glanz JM, France EK et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA296, 1990–1997 (2006).
   Google Scholar
• Pool V, Iskander J. Safety of influenza vaccination during pregnancy. Am. J. Obstet. Gynecol.194, 1200 (2006).
   PubMed Web of Science ®Google Scholar
• CDC. Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine – United States, June–July 2005. MMWR Morb. Mortal. Wkly54(40), 1023–1025 (2005).
   PubMedGoogle Scholar
• Spaeder J, Najjar SS, Gerstenblith G et al. Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits. Am. Heart J.151(4), 844.e1––844.e10 (2006).
   Google Scholar
• Burwen DR, La Voie L, Braun MM, Houck P, Ball R. Evaluating adverse events after vaccination in the Medicare population. Pharmacoepidemiol. Drug Saf.16(7), 753–761 (2007).
   PubMed Web of Science ®Google Scholar
• Rubertone MV, Brundage JF. The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am. J. Public Health92(12), 1900–1904 (2002).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Immunization Registry Progress – United States, 2002. MMWR Morb. Mortal. Wkly Rep.51, 760–762 (2002).
   Google Scholar
• Schwarz B, Hinman A, Abramson J. Universal influenza vaccination in the United States: are we ready? Report of a meeting. J. Infect. Dis.194(Suppl. 2), S147–S154 (2006).
   Google Scholar
• Payne DC, Franzke LH, Stehr-Green PA et al. Development of the Vaccine Analytic Unit’s research agenda for investigating potential adverse events associated with anthrax vaccine adsorbed. Pharmacoepidemiol. Drug Saf.16(1), 46–54 (2007).
   PubMed Web of Science ®Google Scholar